Multi-Stable Stochastic Resonance Based Protection Scheme for Parallel Transmission Lines with UPFC

This paper presents a multi-stable stochastic resonance (MSR) based on complex wavelet transform (CWT) for protecting a double line transmission system with unified power flow controller (UPFC) in one line. The fault detection at the sending end is recognized by the collective sum technique (CST) using the current signals of all the three-phases with heavy background noise. The noisy signal is processed by parameter compensation and the processed signal is decomposed by CWT with different scale frequencies. The spectral energies of each phase can be used to identify the faulty phases. The CWT is used to compute the spectral energies of each phase current. The proposed scheme has been studied for wide variation of operating parameters and compared with two other fault extraction methods such as EMD-based spectral analysis and wavelet transform with post spectral analysis. The test results of the proposed CWT based MSR algorithm indicates that it can accurately detect and classify the fault with in one cycle from fault inception

Maintenance DFMO Increases Survival in High Risk Neuroblastoma.

High risk neuroblastoma (HRNB) accounts for 15% of all pediatric cancer deaths. Despite aggressive therapy approximately half of patients will relapse, typically with only transient responses to second-line therapy. This study evaluated the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) as maintenance therapy to prevent relapse following completion of standard therapy (Stratum 1) or after salvage therapy for relapsed/refractory disease (Stratum 2). This Phase II single agent, single arm multicenter study enrolled from June 2012 to February 2016. Subjects received 2 years of oral DFMO (750 ± 250 mg/m2 twice daily). Event free survival (EFS) and overall survival (OS) were determined on an intention-to-treat (ITT) basis. 101 subjects enrolled on Stratum 1 and 100 were eligible for ITT analysis; two-year EFS was 84% (±4%) and OS 97% (±2%). 39 subjects enrolled on Stratum 2, with a two-year EFS of 54% (±8%) and OS 84% (±6%). DFMO was well tolerated. The median survival time is not yet defined for either stratum. DFMO maintenance therapy for HRNB in remission is safe and associated with high EFS and OS. Targeting ODC represents a novel therapeutic mechanism that may provide a new strategy for preventing relapse in children with HRNB

Maintenance DFMO Increases Survival in High Risk Neuroblastoma.

High risk neuroblastoma (HRNB) accounts for 15% of all pediatric cancer deaths. Despite aggressive therapy approximately half of patients will relapse, typically with only transient responses to second-line therapy. This study evaluated the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) as maintenance therapy to prevent relapse following completion of standard therapy (Stratum 1) or after salvage therapy for relapsed/refractory disease (Stratum 2). This Phase II single agent, single arm multicenter study enrolled from June 2012 to February 2016. Subjects received 2 years of oral DFMO (750 ± 250 mg/m2 twice daily). Event free survival (EFS) and overall survival (OS) were determined on an intention-to-treat (ITT) basis. 101 subjects enrolled on Stratum 1 and 100 were eligible for ITT analysis; two-year EFS was 84% (±4%) and OS 97% (±2%). 39 subjects enrolled on Stratum 2, with a two-year EFS of 54% (±8%) and OS 84% (±6%). DFMO was well tolerated. The median survival time is not yet defined for either stratum. DFMO maintenance therapy for HRNB in remission is safe and associated with high EFS and OS. Targeting ODC represents a novel therapeutic mechanism that may provide a new strategy for preventing relapse in children with HRNB

Additional file 1 of Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial

Additional file 1: Table S1. Cell lines and mice models established. A total of 96 patients enrolled onto the NMTRC009 MGT trial had at least one tumor cell line generated in the laboratory setting. Since many subjects underwent multiple tumor biopsies and/or bone marrow biopsies, subjects may have >1 unique cell line, either from the same tumor obtained from different biopsy dates or from a different disease site (bone marrow). 47 subjects’ tumors underwent successful implantation into a NOD-SCID mouse to generate at least one PDX model. A total of 56 unique PDX models were generated